Nivolumab dose optimization in patients with a complete, partial or stable response (NIVOPTIMIZE-trial)
This study, called NIVOPTIMIZE, is exploring how to give nivolumab, a type of immunotherapy, to people with melanoma (a type of skin cancer) or kidney cancer. Researchers want to see if using a slightly lower dose of nivolumab can still work well, especially after patients have already responded positively to the initial treatment. They are measuring how much of the drug is in the body and if this different dosing affects how the medicine works or if it causes any new side effects. The goal is to find the best way to use nivolumab for long-term treatment, making it potentially more convenient and cost-effective, while still keeping it effective against cancer.
At a glance
What is this study about?
This study is looking at a cancer medicine called nivolumab. Nivolumab is a type of immunotherapy, which means it helps your body's own immune system fight cancer. It's already approved and used to treat certain cancers like melanoma (a serious type of skin cancer) and renal cell carcinoma (a common type of kidney cancer). People in this study would have already started nivolumab treatment and responded well to it, meaning their cancer has either shrunk, been controlled, or even disappeared.
The main idea behind this study is to see if we can give a slightly different, possibly lower, dose of nivolumab once patients have stabilised or improved. Think of it like finding the 'sweet spot' for the medicine – enough to keep working effectively, but maybe not more than needed. The researchers will be checking the levels of the medicine in your blood to understand how the body uses and processes these different doses.
Why does this matter? Finding the most effective dose that might be slightly lower could lead to several benefits. It could potentially reduce side effects, make the treatment easier to manage, and even make it more affordable for the healthcare system. Ultimately, the aim is to improve how patients experience their long-term cancer treatment with nivolumab.
Key takeaways
- This study is about an existing cancer medicine called nivolumab.
- It aims to find the best dose for people with melanoma or kidney cancer who have already responded to treatment.
- The goal is to explore if a slightly lower dose can still be effective, potentially reducing side effects.
- Your health and the medicine's effectiveness will be closely monitored throughout.
- The study could lead to more convenient and cost-effective long-term treatment with nivolumab.
Who may be eligible?
To be considered for this study, you would need to be an adult, at least 18 years old, and you could be any gender. The study is specifically for people who have either melanoma or kidney cancer.
Crucially, you would have already started taking nivolumab for your cancer and shown a good response. This means your cancer would have either completely gone, significantly shrunk, or stayed stable since you began your nivolumab treatment.
There might be other specific medical details that would determine if you can join, but these are the main starting points. Your doctor would be able to check all the criteria carefully with you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Do you have melanoma or kidney cancer?
- Are you currently receiving nivolumab treatment?
- Has your cancer responded positively to your current nivolumab treatment (shrunk, stable, or gone)?
- Are you able to attend regular clinic visits for checks and blood tests?
What does participation involve?
If you join this study, you will continue to receive nivolumab, but the doctors will be looking closely at how different doses affect you. This involves regular blood tests to measure the level of the medicine in your body, particularly before and after some of your doses. They will also check how your immune system is responding.
Throughout the study, you will have regular visits to the clinic to receive your medication and have health checks. The medical team will monitor you very closely for any side effects, particularly any new or severe ones. They will also keep track of your cancer status to ensure the treatment is still working. The total time you would be involved in the study would depend on your treatment plan, but it generally involves regular monitoring over several months.
Potential risks and benefits
Locations (1)
- —UnverifiedNetherlands
Common questions
What is nivolumab?
Nivolumab is a medicine that helps your body's immune system fight certain cancers, like melanoma and kidney cancer.
Why are doctors studying different doses?
Doctors want to find the best possible dose of nivolumab – one that is still very effective against cancer, might reduce side effects, and make long-term treatment easier.
What cancers is this study for?
This study is for people who have melanoma (a type of skin cancer) or renal cell carcinoma (a type of kidney cancer).
Will I get less medicine if I join?
The study is looking at different doses, which might include a slightly reduced dose for some participants after they've already responded well to the initial treatment. Your doctors will explain your specific treatment plan.
Will my safety be monitored closely?
Yes, if you join the study, you will be very closely monitored by the medical team for any changes in your health or any side effects.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.